HC Wainwright Issues Optimistic Estimate for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities researchers at HC Wainwright increased their Q1 2025 earnings estimates for Bicycle Therapeutics in a research report issued on Monday, December 16th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.93) per share for the quarter, up from their previous estimate of ($0.99). HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.49) EPS and FY2028 earnings at ($2.12) EPS.

Several other research firms have also commented on BCYC. Stephens assumed coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. B. Riley reduced their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $15.00 on Thursday. Bicycle Therapeutics has a 12 month low of $12.17 and a 12 month high of $28.67. The firm has a market capitalization of $1.04 billion, a PE ratio of -4.56 and a beta of 0.86. The business has a 50-day moving average of $22.27 and a two-hundred day moving average of $22.61.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period in the prior year, the firm posted ($1.26) EPS. The business’s revenue for the quarter was down 50.0% on a year-over-year basis.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BCYC. Principal Financial Group Inc. acquired a new position in Bicycle Therapeutics in the third quarter worth about $10,028,000. Geode Capital Management LLC lifted its holdings in Bicycle Therapeutics by 79.3% during the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after buying an additional 16,958 shares during the last quarter. Jane Street Group LLC grew its position in shares of Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after acquiring an additional 5,310 shares in the last quarter. State Street Corp increased its holdings in shares of Bicycle Therapeutics by 233.5% in the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock valued at $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Insider Activity

In other news, CEO Kevin Lee sold 3,212 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. This represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the sale, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at $483,141.51. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,840 shares of company stock worth $259,128 over the last ninety days. Corporate insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.